Search clinical trials for: Mantle Cell

Total 49150 results

Janssen Biotech, Inc.
Pharmacyclics LLC.

Approved for marketing

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Relapsed or Refractory Mantle Cell Lymphoma

United States, Brazil, Puerto Rico
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

Lymphoma | Leukemia

United States
University College, London
Cancer Research UK

Completed

Phase III, Multicentre, Randomised Study of Fludarabine/Cyclophosphamide Combination With or Without Rituximab in Patients With Untreated Mantle Cell Lymphoma (MCLPIII)

Lymphoma

United Kingdom, Australia
National Cancer Institute (NCI)

Completed

Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma | Transformed Recurrent Non-Hodgkin Lymphoma

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Terminated

Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial

Cancer
Novartis Pharmaceuticals

Completed

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

United States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
Wake Forest University Health Sciences

Completed

Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies

Primary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma and other conditions

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm

United States
University of Arizona
National Cancer Institute (NCI)

Completed

Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Anaplastic Large Cell Lymphoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

Lymphoma

United States
Lymphoma Study Association

Terminated

Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma

Mantle Cell Lymphoma
Lymphoma Study Association

Completed

Lenalidomide and R-CHOP in B-cell Lymphoma (R2CHOP-1)

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma

France
Montefiore Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Lymphoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer

Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

Myelodysplastic Syndromes | Breast Cancer | Primary Myelofibrosis | Multiple Myeloma | Ovarian Epithelial Cancer | Chronic Myelomonocytic Leukemia | Neutropenia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone... and other conditions

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma

China, Belgium, Thailand, United States, Spain, Canada, Colombia, Italy, Morocco, Brazil, Turkey, Chile, Malaysia, Israel, Portugal, Singapore, Russian Federation, Philippines, Tunisia, Austria, Czechia, Germany, Hungary, India, Poland, R... and more
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BEAM Followed By ASCT For Relapsed B-Cell Non-Hodgkin Lymphoma

Lymphoma

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer

Unspecified Childhood Solid Tumor, Protocol Specific | Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Juvenile Myelomonocytic Leukemia | Burkitt Lymphoma | Secondary... and other conditions

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic Large Cell Lymphoma | Recurrent Adult Lymphoblastic... and other conditions

United States
Weill Medical College of Cornell University

Completed

Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma

Non-Hodgkin's Lymphoma

United States
All For Women Healthcare, Illinois
Medtronic

Completed

Effectiveness of Truclear on Patient Quality of Life (HSCMyomecty)

Heavy Menstrual Bleeding

United States
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell

United States, Australia, France, Belgium, Turkey, Netherlands, Korea, Republic of
Weill Medical College of Cornell University
Millennium Pharmaceuticals, Inc.

Completed

Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL

Non-Hodgkin's Lymphoma

United States
Ohio State University Comprehensive Cancer Center
Millennium Pharmaceuticals, Inc.

Terminated

Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade... and other conditions

United States
Amir Mortazavi
National Cancer Institute (NCI); Arno Therapeutics

Completed

AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma

Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse... and other conditions

United States
Dartmouth-Hitchcock Medical Center
National Cancer Institute (NCI)

Terminated

Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
Emory University

Terminated

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Myelofibrosis | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Acute Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Small Lymphocytic Lymphoma | Graft Versus Host Disease | Chronic Myelogenous Leukemia,...

United States
French Innovative Leukemia Organisation
Lymphoma Study Association

Completed

Mantel Cell Lymphoma Efficacy of Rituximab Maintenance

Mantle Cell Lymphoma

France
Milton S. Hershey Medical Center

Terminated

Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation

Lymphoma | Leukemia | Multiple Myeloma | Hodgkin's Lymphoma | Myelodysplastic Syndrome | Chronic Myelogenous Leukemia

United States
Seagen Inc.

Completed

Safety Study of SGN-CD70A in Cancer Patients

Renal Cell Carcinoma | Diffuse, Large B-Cell, Lymphoma | Mantle-Cell Lymphoma | Follicular Lymphoma, Grade 3

United States
The University of Hong Kong
Janssen, LP

Unknown

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Follicular Lymphoma | Chronic Hepatitis B | Chronic Lymphocytic Leukemia | Mantle-Cell Lymphoma | Lymphoma, Small Lymphocytic | Indolent B-cell Lymphomas | Waldenstrom's Macroglobulinaemia

Hong Kong
National Cancer Institute (NCI)

Completed

Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Lymphoblastic Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom... and other conditions

United States
Millennium Pharmaceuticals, Inc.

Completed

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Transformed Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Burkitt's Lymphoma

United States, Spain, Italy, United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | Burkitt's Lymphoma | T-cell Lymphoma, Excluding Primary Cutaneous T-cell Lymphoma | Transformed Follicular Lymphoma With ≥ 50% Diffuse Large Cell Component

United States
Istituto Scientifico Romagnolo per lo Studio e...

Terminated

Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas (itTRIOlym)

Recurrent Disease | DLBCL | MCL

Italy
Lund University Hospital
Mundipharma Pte Ltd.; Roche Pharma AG; Celgene

Completed

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. (LENA-BERIT)

Mantle Cell Lymphoma

Finland, Denmark, Norway, Sweden
Ohio State University Comprehensive Cancer Center

Completed

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

Lymphoma | Small Intestine Cancer | Multiple Myeloma and Plasma Cell Neoplasm

United States
Ohio State University Comprehensive Cancer Center

Completed

Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

United States
Fondazione Italiana Linfomi ONLUS

Completed

Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL (R2-B)

Mantle Cell Lymphoma

Italy
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Nodal Marginal Zone Lymphoma

United States
Fondazione Italiana Linfomi ONLUS

Unknown

Phase III, Randomized Trial: Lenalidomide vs Observation After Induction With Rituximab Followed by Cht and ASCT in MCL Adult Patients (MCL0208)

MANTLE CELL LYMPHOMA

Italy, Portugal
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

United States, Australia, Brazil, Canada, Mexico, New Zealand, Peru
European Organisation for Research and Treatment...

Completed

Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant

Cancer

Belgium, Switzerland, Italy, France, Germany

Search clinical trials for: Mantle Cell

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations